We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.52%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$7.16B
AUM Growth
+$666M
(+10%)
Cap. Flow
+$831M
Cap. Flow
% of AUM
11.61%
Top 10 Holdings %
Top 10 Hldgs %
17.05%
Holding
983
New
189
Increased
207
Reduced
145
Closed
240
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$146M |
| 2 |
Gilead Sciences
GILD
|
+$116M |
| 3 |
Amazon
AMZN
|
+$86.4M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$84.7M |
| 5 |
Analog Devices
ADI
|
+$80M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$73.2M |
| 2 |
Palo Alto Networks
PANW
|
+$59.8M |
| 3 |
Alkermes
ALKS
|
+$55.3M |
| 4 |
Accenture
ACN
|
+$53.8M |
| 5 |
Johnson & Johnson
JNJ
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.05% |
| 2 | Technology | 29.2% |
| 3 | Financials | 8.76% |
| 4 | Industrials | 7.7% |
| 5 | Communication Services | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Fox Class A
FOXA
$26B
| $7.94M | 0.11% |
258,717
-43,357
| -14% | -$1.47M |
|
227
Jabil
JBL
$36.5B
| $7.86M | 0.11% |
+136,217
| New | +$7.92M |
|
|
OKLO
228
Oklo
OKLO
$7.41B
| $7.81M | 0.11% |
800,000
| – | – |
|
229
Annexon
ANNX
$901M
| $7.8M | 0.11% |
1,261,770
+852,140
| +208% | +$4.61M |
|
|
AGCB
230
DELISTED
Altimeter Growth Corp 2
AGCB
| $7.68M | 0.11% |
775,220
+575,220
| +288% | +$5.69M |
|
231
Workday
WDAY
$41.6B
| $7.55M | 0.11% |
+49,590
| New | +$7.76M |
|
232
Mirum Pharmaceuticals
MIRM
$5.81B
| $7.5M | 0.1% |
+356,952
| New | +$8.59M |
|
233
Freshpet
FRPT
$3.32B
| $7.5M | 0.1% |
149,667
+33,486
| +29% | +$1.58M |
|
234
AlTi Global
ALTI
$483M
| $7.43M | 0.1% |
749,999
| – | – |
|
235
Relay Therapeutics
RLAY
$4.26B
| $7.42M | 0.1% |
331,663
| – | – |
|
|
RACB
236
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $7.37M | 0.1% |
750,000
| – | – |
|
237
Sana Biotechnology
SANA
$943M
| $7.3M | 0.1% |
1,216,916
-106,317
| -8% | -$767K |
|
|
LDHA
238
DELISTED
LDH Growth Corp I Class A Ordinary Shares
LDHA
| $7.26M | 0.1% |
733,000
+433,000
| +144% | +$4.26M |
|
|
BLUE
239
DELISTED
bluebird bio
BLUE
| $7.21M | 0.1% |
+56,928
| New | +$6.44M |
|
|
LGAC
240
DELISTED
Lazard Growth Acquisition Corp. I Ordinary Shares
LGAC
| $7.07M | 0.1% |
712,450
+200,000
| +39% | +$1.97M |
|
241
Walmart Inc
WMT
$888B
| $7.05M | 0.1% |
+163,128
| New | +$7.15M |
|
242
Option Care Health
OPCH
$3.52B
| $7M | 0.1% |
222,566
-134,651
| -38% | -$4.31M |
|
|
AGGR
243
DELISTED
Agile Growth Corp
AGGR
| $6.94M | 0.1% |
699,999
+100,000
| +17% | +$985K |
|
|
ROSS
244
DELISTED
Ross Acquisition Corp II
ROSS
| $6.94M | 0.1% |
700,000
+500,000
| +250% | +$4.93M |
|
245
Zentalis Pharmaceuticals
ZNTL
$358M
| $6.93M | 0.1% |
319,747
+138,475
| +76% | +$3.79M |
|
|
IMGO
246
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $6.88M | 0.1% |
457,136
-214,924
| -32% | -$3.49M |
|
|
INFN
247
DELISTED
Infinera Corporation Common Stock
INFN
| $6.69M | 0.09% |
1,381,690
+734,401
| +113% | +$4.03M |
|
|
CHAA
248
DELISTED
Catcha Investment Corp
CHAA
| $6.64M | 0.09% |
671,000
+471,000
| +236% | +$4.65M |
|
249
Travere Therapeutics
TVTX
$6.05B
| $6.61M | 0.09% |
+268,175
| New | +$6.93M |
|
|
MDRX
250
DELISTED
Veradigm Inc. Common Stock
MDRX
| $6.58M | 0.09% |
431,807
+295,286
| +216% | +$4.78M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Woodline Partners held 983 positions worth $7.16B, up 10% from $6.49B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Woodline Partners deployed $831M of net new capital in Q3 2022, opening 189 new positions and adding to 207 existing holdings. Its largest new stake was Amazon: 683,398 shares worth $77.2M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $73.2M trimmed.
- Woodline Partners's largest Q3 2022 buy was Amazon: 683,398 shares worth $77.2M.
- Woodline Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $146M increase.
- Woodline Partners's biggest Q3 2022 reduction was Eli Lilly, cutting an estimated $73.2M.
- Woodline Partners fully exited Palo Alto Networks in Q3 2022, selling an estimated $59.8M.
- Woodline Partners's ten largest holdings make up 17% of its $7.16B portfolio in Q3 2022.
- Woodline Partners opened 189 new positions and closed 240 in Q3 2022.
- Woodline Partners's portfolio value rose 10% quarter-over-quarter to $7.16B.
Based on Woodline Partners's 13F filing for Q3 2022, filed 14 Nov 2022.